» Articles » PMID: 25320245

Exosomal MiR-135b Shed from Hypoxic Multiple Myeloma Cells Enhances Angiogenesis by Targeting Factor-inhibiting HIF-1

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2014 Oct 17
PMID 25320245
Citations 324
Authors
Affiliations
Soon will be listed here.
Abstract

Exosomes are small endosome-derived vesicles containing a wide range of functional proteins, mRNA, and miRNA. Exosomal miRNA from cancer cells helps modulate the microenvironment. In multiple myeloma (MM), the massive proliferation of malignant plasma cells causes hypoxia. To date, the majority of in vitro hypoxia studies of cancer cells have used acute hypoxic exposure (3-24 hours). Thus, we attempted to clarify the role of MM-derived exosomes in hypoxic bone marrow by using MM cells grown continuously in vitro under chronic hypoxia (hypoxia-resistant MM [HR-MM] cells). The HR-MM cells produced more exosomes than the parental cells under normoxia or acute hypoxia conditions, and miR-135b was significantly upregulated in exosomes from HR-MM cells. Exosomal miR-135b directly suppressed its target factor-inhibiting hypoxia-inducible factor 1 (FIH-1) in endothelial cells. Finally, exosomal miR-135b from HR-MM cells enhanced endothelial tube formation under hypoxia via the HIF-FIH signaling pathway. This in vitro HR myeloma cell model will be useful for investigating MM cell-endothelial cell interactions under hypoxic conditions, which may mimic the in vivo bone marrow microenvironment. Although tumor angiogenesis is regulated by various factors, exosomal miR-135b may be a target for controlling MM angiogenesis.

Citing Articles

Extracellular vesicles in tumor immunity: mechanisms and novel insights.

Kuang L, Wu L, Li Y Mol Cancer. 2025; 24(1):45.

PMID: 39953480 PMC: 11829561. DOI: 10.1186/s12943-025-02233-w.


MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia.

Gregorova J, Vlachova M, Vychytilova-Faltejskova P, Dostalova A, Ruzickova T, Vecera M Hematol Oncol. 2025; 43(1):e70036.

PMID: 39804194 PMC: 11727818. DOI: 10.1002/hon.70036.


Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.

Mohseni A, Salehi F, Rostami S, Hadiloo K, Hashemi M, Baridjavadi Z Stem Cell Res Ther. 2025; 16(1):6.

PMID: 39773361 PMC: 11708188. DOI: 10.1186/s13287-024-04125-0.


Role of vascular endothelium and exosomes in cancer progression and therapy (Review).

Dai Y, Yao Y, He Y, Hu X Int J Oncol. 2024; 66(1).

PMID: 39635838 PMC: 11684794. DOI: 10.3892/ijo.2024.5712.


Therapeutically Harnessing Tumor Cell-Derived Extracellular Vesicles for Multiple Myeloma: Recent Advances and Future Perspectives.

Xiao S, Chen L, Chen Z, Li Q Pharmaceutics. 2024; 16(11).

PMID: 39598562 PMC: 11597712. DOI: 10.3390/pharmaceutics16111439.


References
1.
Matsuyama H, Suzuki H, Nishimori H, Noguchi M, Yao T, Komatsu N . miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 2011; 118(26):6881-92. DOI: 10.1182/blood-2011-05-354654. View

2.
Hideshima T, Mitsiades C, Tonon G, Richardson P, Anderson K . Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7(8):585-98. DOI: 10.1038/nrc2189. View

3.
Kyle R, Rajkumar S . Multiple myeloma. Blood. 2008; 111(6):2962-72. PMC: 2265446. DOI: 10.1182/blood-2007-10-078022. View

4.
Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K . Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer. 2008; 95(3):301-13. DOI: 10.1684/bdc.2008.0600. View

5.
Fu C, Wang J, Xin X, Liu H, Xue S, Ma X . Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients. Exp Ther Med. 2013; 6(4):977-982. PMC: 3797248. DOI: 10.3892/etm.2013.1261. View